Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease

被引:11
|
作者
Ishibashi, K. [2 ]
Kanemaru, K. [3 ]
Saito, Y. [4 ]
Murayama, S. [5 ]
Oda, K.
Ishiwata, K.
Mizusawa, H. [2 ]
Ishii, K. [1 ]
机构
[1] Tokyo Metropolitan Inst Gerontol, Positron Med Ctr, Itabashi Ku, Tokyo 1730022, Japan
[2] Tokyo Med & Dent Univ, Grad Sch, Dept Neurol & Neurol Sci, Tokyo, Japan
[3] Tokyo Metropolitan Geriatr Hosp, Dept Neurol, Tokyo 173, Japan
[4] Tokyo Metropolitan Geriatr Hosp, Dept Pathol, Tokyo 173, Japan
[5] Tokyo Metropolitan Inst Gerontol, Dept Neuropathol, Tokyo 1730022, Japan
来源
ACTA NEUROLOGICA SCANDINAVICA | 2010年 / 122卷 / 01期
基金
日本学术振兴会;
关键词
cerebrospinal fluid; dopamine transporter; homovanillic acid; Parkinson's disease; positron emission tomography; 11C-CFT; POSITRON-EMISSION-TOMOGRAPHY; HOMOVANILLIC-ACID; TRANSPORTER; PROGRESSION; DIAGNOSIS; CSF; REPRODUCIBILITY; BINDING; LIGAND;
D O I
10.1111/j.1600-0404.2009.01255.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives - To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon-11-labeled 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)-tropane (11C-CFT), which can measure the dopamine transporter (DAT) density, in Parkinson's disease (PD). Methods - 11C-CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non-parkinsonian syndromes (NPS) as a control group. Results - In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of 11C-CFT (r = 0.76, P < 0.01). However, in the NPS group, two indices were within the normal range. Conclusions - In PD, CSF HVA concentrations correlate with nigrostriatal dopaminergic function. Therefore, CSF HVA concentrations may be an additional surrogate marker for estimating the remaining nigrostriatal dopaminergic function in case that DAT imaging is unavailable.
引用
收藏
页码:46 / 51
页数:6
相关论文
共 50 条
  • [21] Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease
    Drui, G.
    Carnicella, S.
    Carcenac, C.
    Favier, M.
    Bertrand, A.
    Boulet, S.
    Savasta, M.
    MOLECULAR PSYCHIATRY, 2014, 19 (03) : 358 - 367
  • [22] Inhibition of proteasome function in rat nigrostriatal dopaminergic neurons as an animal model of Parkinson's disease for studying neuroprotective compounds
    Lorenc-Koci, Elzbieta
    Lenda, Tomasz
    Domin, Helena
    Jantas, Danuta
    Smialowska, Maria
    Zapala, Malgorzata
    Konieczny, Jolanta
    PHARMACOLOGICAL REPORTS, 2010, 62 : 33 - 33
  • [23] Reduced coupling of global brain function and cerebrospinal fluid dynamics in Parkinson's disease
    Wang, Zhiyun
    Song, Zhe
    Zhou, Cheng
    Fang, Yi
    Gu, Luyan
    Yang, Wenyi
    Gao, Ting
    Si, Xiaoli
    Liu, Yi
    Chen, Ying
    Guan, Xiaojun
    Guo, Tao
    Wu, Jingjing
    Bai, Xueqing
    Zhang, Minming
    Zhang, Baorong
    Pu, Jiali
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2023, 43 (08): : 1328 - 1339
  • [24] Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration
    Rite, I.
    Argueelles, S.
    Venero, J. L.
    Garcia-Rodriguez, S.
    Ayala, A.
    Cano, J.
    Machado, A.
    JOURNAL OF NEUROSCIENCE RESEARCH, 2007, 85 (16) : 3607 - 3618
  • [25] Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson’s disease
    T. Müller
    Wilfried Kuhn
    Thomas Büttner
    Ernst Eising
    H. Coenen
    Martin Haas
    Horst Przuntek
    Journal of Neurology, 1998, 245 : 659 - 664
  • [26] Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease
    Sano, Hiromi
    Murata, Miho
    Nambu, Atsushi
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 (02) : 371 - 381
  • [27] Nigrosome 1 visibility and its association with nigrostriatal dopaminergic loss in Parkinson's disease
    Kim, Han-Kyeol
    Kim, Tae Won
    Baek, Min Seok
    Kim, Eung Yeop
    Sung, Young Hee
    Lee, Jae Hoon
    Ryu, Young Hoon
    Ahn, Sung Jun
    Yoo, Han Soo
    Lyoo, Chul Hyoung
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (06) : 1639 - 1647
  • [28] Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway
    Booij, Jan
    Berendse, Henk W.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 310 (1-2) : 40 - 43
  • [29] Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease
    Ouchi, Y
    Kanno, T
    Okada, H
    Yoshikawa, E
    Futatsubashi, M
    Nobezawa, S
    Torizuka, T
    Tanaka, K
    BRAIN, 2001, 124 : 784 - 792
  • [30] Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson’s disease
    G Drui
    S Carnicella
    C Carcenac
    M Favier
    A Bertrand
    S Boulet
    M Savasta
    Molecular Psychiatry, 2014, 19 : 358 - 367